Log in to save to my catalogue

Clinicopathological, molecular, and prognostic features of colorectal carcinomas with KRAS c.34G>T (...

Clinicopathological, molecular, and prognostic features of colorectal carcinomas with KRAS c.34G>T (...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11448363

Clinicopathological, molecular, and prognostic features of colorectal carcinomas with KRAS c.34G>T (p.G12C) mutation

About this item

Full title

Clinicopathological, molecular, and prognostic features of colorectal carcinomas with KRAS c.34G>T (p.G12C) mutation

Publisher

England: John Wiley & Sons, Inc

Journal title

Cancer science, 2024-10, Vol.115 (10), p.3455-3465

Language

English

Formats

Publication information

Publisher

England: John Wiley & Sons, Inc

More information

Scope and Contents

Contents

Evidence indicates that combinations of anti‐EGFR antibodies and KRAS p.G12C (c.34G>T) inhibitors can be an effective treatment strategy for advanced colorectal cancer. We hypothesized that KRAS c.34G>T (p.G12C)‐mutated colorectal carcinoma might be a distinct tumor subtype. We utilized a prospective cohort incident tumor biobank (including 1347 co...

Alternative Titles

Full title

Clinicopathological, molecular, and prognostic features of colorectal carcinomas with KRAS c.34G>T (p.G12C) mutation

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11448363

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11448363

Other Identifiers

ISSN

1347-9032,1349-7006

E-ISSN

1349-7006

DOI

10.1111/cas.16262

How to access this item